Skip to navigation Skip to content

Rheumatoid arthritis (RA) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051134

Expand/Collapse all sectionsExpand all


RA restriction and item codes

Do not share this attachment externally. See Freedom of Information - Information Publication Scheme.

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.pngPBS RA restriction and item codes

Calculator

\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-attachment.pngNext assessment date (NAD) calculator

Contact details

PBS Complex Drugs Programs

Forms

Rheumatoid arthritis - initial authority application (PB109)

Rheumatoid arthritis - continuing authority application (PB111)

Rheumatoid arthritis - change, recommencement or demonstration of response authority application (PB247)

Rheumatoid arthritis - change of treatment after resolution of critical shortage of tocilizumab authority application (PB324)

Services Australia website

Arthritis - rheumatoid arthritis

External websites

PBS schedule for Rheumatoid arthritis

FAQs

See the Resources page in Processing Complex Authority Required Listings for FAQs relevant to all Complex programs.

Item

Description

1

Question: Does the first continuing have to be after 12 weeks?

Answer: Yes, the patient must have at least 12 weeks of therapy to demonstrate a response to treatment. Measure 12 weeks from approval date.

2

Question: The prescriber provided both ESR and CRP at baseline but is only responding on CRP currently - Is this ok?

Answer: Yes. As long as both bloods were qualifying for entry at baseline, only responding on one of them currently is ok.